<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Pediapharm Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/8OUTkZLWJYYTPyeEkZDZMA==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2019, Pediapharm Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Mon, 07 Jan 2019 19:35:47 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2019/01/07/1681607/0/en/Medexus-Files-Business-Acquisition-Report.html</guid> <link>https://www.globenewswire.com/news-release/2019/01/07/1681607/0/en/Medexus-Files-Business-Acquisition-Report.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Medexus Files Business Acquisition Report</title> <description><![CDATA[<p align="justify">MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “<strong>Company</strong>”<strong>)</strong> (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report <strong>(“BAR”)</strong> on SEDAR (<a href="https://www.globenewswire.com/Tracker?data=sbP_3pqPGuT0hbVa9hUCIZB240fgDOAYIRm8T_kHLMcLWGyHs3h-D1k7190d4hu9Gk46BFqaC5edtG7rP1UUcw==" rel="nofollow" target="_blank" title=""><u>www.sedar.com</u></a>) in relation to the previously announced transaction that occurred on October 16, 2018.<br></p>]]></description> <pubDate>Mon, 07 Jan 2019 19:35 GMT</pubDate> <dc:identifier>1681607</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Mon, 07 Jan 2019 19:35 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> <dc:keyword>Pediapharm</dc:keyword> <dc:keyword>Medexus</dc:keyword> <dc:keyword>acquisition</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2019/01/07/1681607/0/fr/Medexus-pr%C3%A9sente-une-d%C3%A9claration-d-acquisition.html</guid> <link>https://www.globenewswire.com/news-release/2019/01/07/1681607/0/fr/Medexus-pr%C3%A9sente-une-d%C3%A9claration-d-acquisition.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Medexus présente une déclaration d’acquisition</title> <description><![CDATA[<p align="justify">MONTRÉAL, 07 janv. 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « Société ») (TSXV : MDP, OTCQB : PDDPF) a annoncé aujourd’hui la présentation d’une déclaration d’acquisition d’entreprise (« DAE ») sur SEDAR (www.sedar.com) dans le cadre de la transaction annoncée précédemment qui a eu lieu le 16 octobre 2018.<br></p>]]></description> <pubDate>Mon, 07 Jan 2019 19:35 GMT</pubDate> <dc:identifier>1681607</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Mon, 07 Jan 2019 19:35 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> <dc:keyword>Pediapharm</dc:keyword> <dc:keyword>Medexus</dc:keyword> <dc:keyword>acquisition</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/18/1668379/0/fr/Medexus-annonce-la-nomination-d-un-nouveau-chef-de-la-direction-d-un-nouveau-pr%C3%A9sident-du-conseil-d-administration-d-autres-mises-%C3%A0-jour-organisationnelles-et-des-attributions-d-ac.html</guid> <link>https://www.globenewswire.com/news-release/2018/12/18/1668379/0/fr/Medexus-annonce-la-nomination-d-un-nouveau-chef-de-la-direction-d-un-nouveau-pr%C3%A9sident-du-conseil-d-administration-d-autres-mises-%C3%A0-jour-organisationnelles-et-des-attributions-d-ac.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Medexus annonce la nomination d’un nouveau chef de la direction, d’un nouveau président du conseil d’administration, d’autres mises à jour organisationnelles et des attributions d’actions incitatives</title> <description><![CDATA[<p align="justify">MONTRÉAL, 17 déc. 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « <strong>société</strong> ») (TSXV : PDP, OTCQB : PDDPF) a annoncé aujourd’hui des changements organisationnels visant à améliorer le positionnement de la société alors que celle-ci continue d’intégrer les acquisitions transformatrices de Medexus Inc. (« <strong>Medexus</strong> ») et de Medac Pharma, Inc. (« <strong>Medac Pharma</strong> »).<br></p>]]></description> <pubDate>Tue, 18 Dec 2018 00:03 GMT</pubDate> <dc:identifier>1668379</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Tue, 18 Dec 2018 00:02 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> <dc:subject>Stock Market News</dc:subject> <dc:keyword>acquisition</dc:keyword> <dc:keyword>pédiatrique</dc:keyword> <dc:keyword>rhumatologie</dc:keyword> <dc:keyword>société pharmaceutique spécial</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/17/1668262/0/en/Medexus-Announces-New-Chief-Executive-Officer-Chair-of-the-Board-of-Directors-Other-Organizational-Updates-and-Equity-Incentive-Grants.html</guid> <link>https://www.globenewswire.com/news-release/2018/12/17/1668262/0/en/Medexus-Announces-New-Chief-Executive-Officer-Chair-of-the-Board-of-Directors-Other-Organizational-Updates-and-Equity-Incentive-Grants.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants</title> <description><![CDATA[<p align="justify">MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “<strong>Company</strong>”) (TSXV: PDP, OTCQB: PDDPF) today announced organizational changes designed to better position the Company as it continues to integrate the transformative acquisitions of Medexus Inc. (“<strong>Medexus</strong>”) and medac Pharma, Inc. (“<strong>Medac Pharma</strong>”).<br></p>]]></description> <pubDate>Mon, 17 Dec 2018 19:30 GMT</pubDate> <dc:identifier>1668262</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Mon, 17 Dec 2018 19:30 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> <dc:keyword>acquisition</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/14/1667510/0/fr/Pediapharm-annonce-le-changement-de-son-nom-la-consolidation-de-ses-actions-et-le-remboursement-de-ses-d%C3%A9bentures.html</guid> <link>https://www.globenewswire.com/news-release/2018/12/14/1667510/0/fr/Pediapharm-annonce-le-changement-de-son-nom-la-consolidation-de-ses-actions-et-le-remboursement-de-ses-d%C3%A9bentures.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce le changement de son nom, la consolidation de ses actions et le remboursement de ses débentures</title> <description><![CDATA[<p align="center">NE PAS DISTRIBUER AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS.</p>]]></description> <pubDate>Fri, 14 Dec 2018 21:57 GMT</pubDate> <dc:identifier>1667510</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Fri, 14 Dec 2018 21:57 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/13/1666975/0/en/Pediapharm-Announces-Name-Change-Consolidation-and-Debenture-Repayment.html</guid> <link>https://www.globenewswire.com/news-release/2018/12/13/1666975/0/en/Pediapharm-Announces-Name-Change-Consolidation-and-Debenture-Repayment.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Name Change, Consolidation and Debenture Repayment</title> <description><![CDATA[<p align="justify"><strong>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.</strong></p>]]></description> <pubDate>Thu, 13 Dec 2018 20:44 GMT</pubDate> <dc:identifier>1666975</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Medexus Pharmaceuticals Inc.</dc:contributor> <dc:modified>Thu, 13 Dec 2018 20:44 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> <dc:keyword>specialty pharma company</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>AGM</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/27/1657370/0/en/Pediapharm-Announces-Q2-Results-Record-Adjusted-EBITDA-Record-Revenue-and-13th-Consecutive-Year-Over-Year-Quarterly-Revenue-Growth.html</guid> <link>https://www.globenewswire.com/news-release/2018/11/27/1657370/0/en/Pediapharm-Announces-Q2-Results-Record-Adjusted-EBITDA-Record-Revenue-and-13th-Consecutive-Year-Over-Year-Quarterly-Revenue-Growth.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Q2 Results – Record Adjusted EBITDA, Record Revenue and 13th Consecutive Year-Over-Year Quarterly Revenue Growth</title> <description><![CDATA[<p align="justify">NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.</p>]]></description> <pubDate>Tue, 27 Nov 2018 13:00 GMT</pubDate> <dc:identifier>1657370</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Tue, 27 Nov 2018 13:01 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:keyword>specialty pharma company</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>pediatric</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/27/1657370/0/fr/Pediapharm-annonce-les-r%C3%A9sultats-de-son-deuxi%C3%A8me-trimestre-BAIIA-ajust%C3%A9-record-ventes-records-et-un-13e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</guid> <link>https://www.globenewswire.com/news-release/2018/11/27/1657370/0/fr/Pediapharm-annonce-les-r%C3%A9sultats-de-son-deuxi%C3%A8me-trimestre-BAIIA-ajust%C3%A9-record-ventes-records-et-un-13e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce les résultats de son deuxième trimestre – BAIIA ajusté record, ventes records et un 13e trimestre consécutif de croissance d’un exercice à l’autre</title> <description><![CDATA[<p align="justify">CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS.</p>]]></description> <pubDate>Tue, 27 Nov 2018 13:00 GMT</pubDate> <dc:identifier>1657370</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Tue, 27 Nov 2018 13:01 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:keyword>specialty pharma company</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>pediatric</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/19/1624134/0/fr/Pediapharm-annonce-la-cl%C3%B4ture-d-acquisitions-transformatrices-de-diversification-et-d-expansion-de-la-plateforme-pour-une-croissance-future.html</guid> <link>https://www.globenewswire.com/news-release/2018/10/19/1624134/0/fr/Pediapharm-annonce-la-cl%C3%B4ture-d-acquisitions-transformatrices-de-diversification-et-d-expansion-de-la-plateforme-pour-une-croissance-future.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce la clôture d’acquisitions transformatrices, de diversification et d’expansion de la plateforme pour une croissance future</title> <description><![CDATA[<p>CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS.</p>]]></description> <pubDate>Fri, 19 Oct 2018 14:50 GMT</pubDate> <dc:identifier>1624134</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Fri, 19 Oct 2018 14:50 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/16/1622330/0/en/Pediapharm-Announces-Closing-of-Transformative-Acquisitions-Diversifying-and-Expanding-the-Platform-for-Future-Growth.html</guid> <link>https://www.globenewswire.com/news-release/2018/10/16/1622330/0/en/Pediapharm-Announces-Closing-of-Transformative-Acquisitions-Diversifying-and-Expanding-the-Platform-for-Future-Growth.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Closing of Transformative Acquisitions, Diversifying and Expanding the Platform for Future Growth</title> <description><![CDATA[<p>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.</p>]]></description> <pubDate>Tue, 16 Oct 2018 21:12 GMT</pubDate> <dc:identifier>1622330</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Tue, 16 Oct 2018 21:12 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>acquisition</dc:keyword> <dc:keyword>financing</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/15/1621491/0/fr/Pediapharm-annonce-la-cl%C3%B4ture-de-l-offre-de-re%C3%A7us-de-souscription-pour-un-produit-brut-total-de-62-M.html</guid> <link>https://www.globenewswire.com/news-release/2018/10/15/1621491/0/fr/Pediapharm-annonce-la-cl%C3%B4ture-de-l-offre-de-re%C3%A7us-de-souscription-pour-un-produit-brut-total-de-62-M.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce la clôture de l’offre de reçus de souscription pour un produit brut total de 62 M$</title> <description><![CDATA[<p>CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS.</p>]]></description> <pubDate>Mon, 15 Oct 2018 18:21 GMT</pubDate> <dc:identifier>1621491</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Mon, 15 Oct 2018 18:21 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/11/1620184/0/en/Pediapharm-Announces-Closing-of-Subscription-Receipt-Offering-for-Total-Gross-Proceeds-of-62-Million.html</guid> <link>https://www.globenewswire.com/news-release/2018/10/11/1620184/0/en/Pediapharm-Announces-Closing-of-Subscription-Receipt-Offering-for-Total-Gross-Proceeds-of-62-Million.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Closing of Subscription Receipt Offering for Total Gross Proceeds of $62 Million</title> <description><![CDATA[<p align="justify">NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.</p>]]></description> <pubDate>Thu, 11 Oct 2018 16:14 GMT</pubDate> <dc:identifier>1620184</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Thu, 11 Oct 2018 16:14 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>acquisition</dc:keyword> <dc:keyword>financing</dc:keyword> <dc:keyword>private placement</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/09/12/1570085/0/fr/Pr%C3%A9sentation-corporative-de-Pediapharm.html</guid> <link>https://www.globenewswire.com/news-release/2018/09/12/1570085/0/fr/Pr%C3%A9sentation-corporative-de-Pediapharm.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Présentation corporative de Pediapharm</title> <description><![CDATA[<p align="justify">NE PAS DISTRIBUER AUX SERVICES DE TRANSMISSION DE NOUVELLES DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS. LE NON-RESPECT DE CETTE RESTRICTION PEUT CONSTITUER UNE VIOLATION DE LA LÉGISLATION EN VALEURS MOBILIÈRES DES ÉTATS-UNIS.</p>]]></description> <pubDate>Wed, 12 Sep 2018 19:52 GMT</pubDate> <dc:identifier>1570085</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Wed, 12 Sep 2018 19:52 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/09/12/1570070/0/en/Pediapharm-Files-Corporate-Presentation.html</guid> <link>https://www.globenewswire.com/news-release/2018/09/12/1570070/0/en/Pediapharm-Files-Corporate-Presentation.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Files Corporate Presentation</title> <description><![CDATA[<p align="left">NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.</p>]]></description> <pubDate>Wed, 12 Sep 2018 19:17 GMT</pubDate> <dc:identifier>1570070</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Wed, 12 Sep 2018 19:17 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>acquisition</dc:keyword> <dc:keyword>financing</dc:keyword> <dc:keyword>private placement</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>specialty pharma company</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/09/12/1569710/0/fr/Pediapharm-annonce-des-acquisitions-transformatrices-et-un-placement-de-60-millions-de-dollars-de-re%C3%A7us-de-souscription.html</guid> <link>https://www.globenewswire.com/news-release/2018/09/12/1569710/0/fr/Pediapharm-annonce-des-acquisitions-transformatrices-et-un-placement-de-60-millions-de-dollars-de-re%C3%A7us-de-souscription.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce des acquisitions transformatrices et un placement de 60 millions de dollars de reçus de souscription</title> <description><![CDATA[<p style="border-style:none;">NON DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS LE NON-RESPECT DE CETTE RESTRICTION PEUT CONSTITUER UNE VIOLATION DE LA LÉGISLATION AMÉRICAINE SUR LES VALEURS MOBILIÈRES.</p>]]></description> <pubDate>Wed, 12 Sep 2018 12:08 GMT</pubDate> <dc:identifier>1569710</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Wed, 12 Sep 2018 12:08 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/09/07/1567782/0/en/Pediapharm-Announces-Transformative-Acquisitions-and-60-Million-Offering-of-Subscription-Receipts.html</guid> <link>https://www.globenewswire.com/news-release/2018/09/07/1567782/0/en/Pediapharm-Announces-Transformative-Acquisitions-and-60-Million-Offering-of-Subscription-Receipts.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Transformative Acquisitions and $60 Million Offering of Subscription Receipts</title> <description><![CDATA[<p>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.<br></p>]]></description> <pubDate>Fri, 07 Sep 2018 00:29 GMT</pubDate> <dc:identifier>1567782</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Fri, 07 Sep 2018 00:29 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>specialty pharma company</dc:keyword> <dc:keyword>acquisition</dc:keyword> <dc:keyword>private placement</dc:keyword> <dc:keyword>pediatric</dc:keyword> <dc:keyword>rheumatology</dc:keyword> <dc:keyword>financing</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/08/27/1556851/0/en/Pediapharm-Announces-Q1-Results-Record-Revenue-and-12th-Consecutive-Year-Over-Year-Quarterly-Growth.html</guid> <link>https://www.globenewswire.com/news-release/2018/08/27/1556851/0/en/Pediapharm-Announces-Q1-Results-Record-Revenue-and-12th-Consecutive-Year-Over-Year-Quarterly-Growth.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Q1 Results – Record Revenue and 12th Consecutive Year-Over-Year Quarterly Growth</title> <description><![CDATA[<p align="center">NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</p>]]></description> <pubDate>Mon, 27 Aug 2018 12:00 GMT</pubDate> <dc:identifier>1556851</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Mon, 27 Aug 2018 12:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/08/27/1556851/0/fr/Pediapharm-annonce-les-r%C3%A9sultats-de-son-premier-trimestre-des-ventes-records-et-un-12e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</guid> <link>https://www.globenewswire.com/news-release/2018/08/27/1556851/0/fr/Pediapharm-annonce-les-r%C3%A9sultats-de-son-premier-trimestre-des-ventes-records-et-un-12e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce les résultats de son premier trimestre – des ventes records et un 12e trimestre consécutif de croissance d’un exercice à l’autre</title> <description><![CDATA[<p align="center">N’EST PAS DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS</p>]]></description> <pubDate>Mon, 27 Aug 2018 12:00 GMT</pubDate> <dc:identifier>1556851</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Mon, 27 Aug 2018 12:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/07/18/1538854/0/en/Pediapharm-Announces-Annual-Audited-Financial-Results-61-Annual-Revenue-Growth-and-11th-Consecutive-Year-over-year-Quarterly-Growth.html</guid> <link>https://www.globenewswire.com/news-release/2018/07/18/1538854/0/en/Pediapharm-Announces-Annual-Audited-Financial-Results-61-Annual-Revenue-Growth-and-11th-Consecutive-Year-over-year-Quarterly-Growth.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm Announces Annual Audited Financial Results – 61% Annual Revenue Growth and 11th Consecutive Year-over-year Quarterly Growth</title> <description><![CDATA[<p align="center">NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</p>]]></description> <pubDate>Wed, 18 Jul 2018 12:00 GMT</pubDate> <dc:identifier>1538854</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Wed, 18 Jul 2018 12:01 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/07/18/1538854/0/fr/Pediapharm-annonce-ses-r%C3%A9sultats-financiers-audit%C3%A9s-annuels-hausse-annuelle-de-61-des-revenus-et-11e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</guid> <link>https://www.globenewswire.com/news-release/2018/07/18/1538854/0/fr/Pediapharm-annonce-ses-r%C3%A9sultats-financiers-audit%C3%A9s-annuels-hausse-annuelle-de-61-des-revenus-et-11e-trimestre-cons%C3%A9cutif-de-croissance-d-un-exercice-%C3%A0-l-autre.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:PDP</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:PDDPF</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA70533E1088</category> <title>Pediapharm annonce ses résultats financiers audités annuels - hausse annuelle de 61% des revenus et 11e trimestre consécutif de croissance d’un exercice à l’autre</title> <description><![CDATA[<p align="center">N’EST PAS DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS</p>]]></description> <pubDate>Wed, 18 Jul 2018 12:00 GMT</pubDate> <dc:identifier>1538854</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Pediapharm Inc.</dc:contributor> <dc:modified>Wed, 18 Jul 2018 12:01 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </item> </channel> </rss>